These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 26149321)

  • 1. Optimizing Value From Cardiac Rehabilitation: A Cost-Utility Analysis Comparing Age, Sex, and Clinical Subgroups.
    Leggett LE; Hauer T; Martin BJ; Manns B; Aggarwal S; Arena R; Austford LD; Meldrum D; Ghali W; Knudtson ML; Norris CM; Stone JA; Clement F
    Mayo Clin Proc; 2015 Aug; 90(8):1011-20. PubMed ID: 26149321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
    Kourlaba G; Fragoulakis V; Maniadakis N
    Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Community or patient preferences for cost-effectiveness of cardiac rehabilitation: does it matter?
    Oldridge N; Furlong W; Perkins A; Feeny D; Torrance GW
    Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):608-15. PubMed ID: 18800005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of cardiac rehabilitation program delivery models in patients at varying cardiac risk, reason for referral, and sex.
    Papadakis S; Reid RD; Coyle D; Beaton L; Angus D; Oldridge N
    Eur J Cardiovasc Prev Rehabil; 2008 Jun; 15(3):347-53. PubMed ID: 18525392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.
    Chan PS; Nallamothu BK; Gurm HS; Hayward RA; Vijan S
    Circulation; 2007 May; 115(18):2398-409. PubMed ID: 17452609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative outcomes and cost-utility following surgical treatment of focal lumbar spinal stenosis compared with osteoarthritis of the hip or knee: part 2--estimated lifetime incremental cost-utility ratios.
    Rampersaud YR; Tso P; Walker KR; Lewis SJ; Davey JR; Mahomed NN; Coyte PC
    Spine J; 2014 Feb; 14(2):244-54. PubMed ID: 24239803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of sirolimus-eluting stents.
    Shrive FM; Manns BJ; Galbraith PD; Knudtson ML; Ghali WA;
    CMAJ; 2005 Feb; 172(3):345-51. PubMed ID: 15684117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness and cost-effectiveness of the implantable miniature telescope.
    Brown GC; Brown MM; Lieske HB; Lieske PA; Brown KS; Lane SS
    Ophthalmology; 2011 Sep; 118(9):1834-43. PubMed ID: 21723614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of sevelamer in patients with end-stage renal disease.
    Manns B; Klarenbach S; Lee H; Culleton B; Shrive F; Tonelli M
    Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial.
    Henriksson M; Epstein DM; Palmer SJ; Sculpher MJ; Clayton TC; Pocock SJ; Henderson RA; Buxton MJ; Fox KA
    Heart; 2008 Jun; 94(6):717-23. PubMed ID: 18032459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using triple antiplatelet therapy in patients with non-ST elevation acute coronary syndrome managed invasively: a cost-effectiveness analysis.
    Latour-Pérez J; de Miguel Balsa E; Betegón L; Badia X
    Value Health; 2008; 11(5):853-61. PubMed ID: 18489507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A short course of cardiac rehabilitation program is highly cost effective in improving long-term quality of life in patients with recent myocardial infarction or percutaneous coronary intervention.
    Yu CM; Lau CP; Chau J; McGhee S; Kong SL; Cheung BM; Li LS
    Arch Phys Med Rehabil; 2004 Dec; 85(12):1915-22. PubMed ID: 15605326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
    Zhang Z; Mahoney EM; Kolm P; Spertus J; Caro J; Willke R; Weintraub WS
    Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The incremental cost effectiveness of in-patient versus out-patient rehabilitation after total hip arthroplasty - results of a pilot investigation.
    Krummenauer F; Günther KP; Witzlebf WC
    Eur J Med Res; 2008 Jun; 13(6):267-74. PubMed ID: 18558552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.
    Pradelli L; Iannazzo S; Zaniolo O
    Am J Cardiovasc Drugs; 2009; 9(6):383-92. PubMed ID: 19929036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of alternative treatments for depression in low-income women.
    Beil H; Beeber LS; Schwartz TA; Lewis G
    J Ment Health Policy Econ; 2013 Jun; 16(2):55-65. PubMed ID: 23999203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model.
    Patel JJ; Mendes MA; Bounthavong M; Christopher ML; Boggie D; Morreale AP
    J Eval Clin Pract; 2012 Apr; 18(2):247-55. PubMed ID: 20846318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.
    Yao G; Freemantle N; Calvert MJ; Bryan S; Daubert JC; Cleland JG
    Eur Heart J; 2007 Jan; 28(1):42-51. PubMed ID: 17110403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of coronary stenting and abciximab for patients with acute myocardial infarction: results from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial.
    Bakhai A; Stone GW; Grines CL; Murphy SA; Githiora L; Berezin RH; Cox DA; Stuckey T; Griffin JJ; Tcheng JE; Cohen DJ;
    Circulation; 2003 Dec; 108(23):2857-63. PubMed ID: 14610016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.